Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Tuesday

Stoke Therapeutics (NASDAQ:STOK) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $5.32 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 5:00 PM ET.

Stoke Therapeutics Price Performance

Shares of STOK opened at $38.31 on Tuesday. The firm has a market cap of $2.19 billion, a P/E ratio of 57.18 and a beta of 1.07. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $39.81. The company has a 50 day simple moving average of $32.31 and a two-hundred day simple moving average of $29.22.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Stoke Therapeutics during the 4th quarter valued at $145,000. Finally, LPL Financial LLC purchased a new position in Stoke Therapeutics during the 4th quarter valued at $234,000.

Analyst Ratings Changes

STOK has been the subject of a number of research reports. HC Wainwright upped their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a report on Monday, January 5th. Wolfe Research started coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target on the stock. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Chardan Capital raised their price objective on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $39.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.